Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/119223
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Intraseason decline in influenza vaccine effectiveness during the 2016 southern hemisphere influenza season: a test-negative design study and phylogenetic assessment
Author: Regan, A.
Fielding, J.
Chilver, M.
Carville, K.
Minney-Smith, C.
Grant, K.
Thomson, C.
Hahesy, T.
Deng, Y.
Stocks, N.
Sullivan, S.
Citation: Vaccine, 2019; 37(19):2634-2641
Publisher: Elsevier
Issue Date: 2019
ISSN: 0264-410X
1873-2518
Statement of
Responsibility: 
Annette K.Regan, James E.Fielding, Monique B.Chilver, Kylie S.Carville, Cara A.Minney-Smith, Kristina A.Grant, Chloe Thomson, Trish Hahesy, Yi-Mo Deng, Nigel Stocks, Sheena G.Sullivan
Abstract: BACKGROUND:We estimated the effectiveness of seasonal inactivated influenza vaccine and the potential influence of timing of immunization on vaccine effectiveness (VE) using data from the 2016 southern hemisphere influenza season. METHODS:Data were pooled from three routine syndromic sentinel surveillance systems in general practices in Australia. Each system routinely collected specimens for influenza testing from patients presenting with influenza-like illness. Next generation sequencing was used to characterize viruses. Using a test-negative design, VE was estimated based on the odds of vaccination among influenza-positive cases as compared to influenza-negative controls. Subgroup analyses were used to estimate VE by type, subtype and lineage, as well as age group and time between vaccination and symptom onset. RESULTS:A total of 1085 patients tested for influenza in 2016 were included in the analysis, of whom 447 (41%) tested positive for influenza. The majority of detections were influenza A/H3N2 (74%). One-third (31%) of patients received the 2016 southern hemisphere formulation influenza vaccine. Overall, VE was estimated at 40% (95% CI: 18-56%). VE estimates were highest for patients immunized within two months prior to symptom onset (VE: 60%; 95% CI: 26-78%) and lowest for patients immunized >4 months prior to symptom onset (VE: 19%; 95% CI: -73-62%). DISCUSSION:Overall, the 2016 influenza vaccine showed good protection against laboratory-confirmed infection among general practice patients. Results by duration of vaccination suggest a significant decline in effectiveness during the 2016 influenza season, indicating immunization close to influenza season offered optimal protection.
Keywords: Case-control study; Influenza; Influenza vaccines; Test-negative design; Vaccine effectiveness
Rights: Crown Copyright © 2019 Published by Elsevier Ltd. All rights reserved.
RMID: 0030112675
DOI: 10.1016/j.vaccine.2019.02.027
Grant ID: http://purl.org/au-research/grants/nhmrc/1138425
Appears in Collections:Agriculture, Food and Wine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.